Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05804370 · ClinicalTrials.gov registry record · Phase 3
Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
A Phase 3 study of Ovarian Cancer, sponsored by NX Development.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 170
- Enrollment target
- 6
- Study locations
NCT05804370: Recruiting Phase 3 study of Ovarian Cancer, sponsored by NX Development.
NCT05804370 is a Phase 3 study of Ovarian Cancer that is actively recruiting participants, run by NX Development. The registered enrollment target is 170 participants, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (77% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05804370, a Phase 3 study of Ovarian Cancer, is actively recruiting participants, sponsored by NX Development.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 170 participants
- Enrollment target
- 6
- Study locations
Study Summary
This Phase 3 study is designed to investigate the safety, diagnostic performance, and clinical usefulness of Gleolan for the real-time detection and visualization of epithelial ovarian cancer tumors during debulking surgery. The study is planned to run for about 18 months with individual study participation lasting about two (2) weeks.
Primary Outcome
Percentage of participants with at least one suspected ovarian cancer lesion (including lymph nodes) where Gleolan-induced FL is confirmed by central histopathology (Standard of Truth) to be tumor that was not detected during SoC debulking, among all participants who meet the eligibility criteria for the study and receive any amount of Gleolan.
Conditions Studied
Interventions
- DRUG Gleolan
Study Locations (6)
Maryland
- Luminis Health Anne Arundel Medical Center - Annapolis
- University of Maryland - Baltimore
Arizona
- Mayo Clinic Arizona - Phoenix
Minnesota
- Mayo Clinic Methodist Campus - Rochester
New York
- Mount Sinai - New York
Pennsylvania
- WellSpan Health - York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2024-05-30 |
| Est. Completion | 2027-05 |
| Phase | Phase 3 |
What NCT05804370 shows while recruiting
NCT05804370 is an interventional study that assigns participants to a tested intervention. The registered 170 participants enrollment target is mid-sized for trials with a published cap, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which Gleolan is the first listed.
NCT05804370 lists 6 locations in 5 states (Maryland, Arizona, Minnesota).
Frequently Asked Questions
What is clinical trial NCT05804370 about?
NCT05804370 is a clinical study titled "Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)". This Phase 3 study is designed to investigate the safety, diagnostic performance, and clinical usefulness of Gleolan for the real-time detection and visualization of epithelial ovarian cancer tumors during debulking surgery. The study is planned to run for about 18 months with individual study parti...
What is the current status of trial NCT05804370?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 170 participants. The study started on 2024-05-30. Estimated completion is 2027-05.
What conditions does trial NCT05804370 study?
This clinical trial studies the following conditions: Ovarian Cancer.
What interventions are being tested in trial NCT05804370?
The interventions under investigation include: Gleolan (DRUG).
Who is sponsoring clinical trial NCT05804370?
This trial is sponsored by NX Development, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05804370 being conducted?
This trial has 6 study locations across Arizona, Maryland, Minnesota, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05804370's enrollment target sits among peer trials
170 112th of 322 higher than 209 of 322 other Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
RECRUITING · Phase 3
-
Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
RECRUITING · Phase 3
-
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 3
-
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
RECRUITING · Phase 3
-
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
RECRUITING · Phase 3
-
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02016430 · 170 participants · NA
Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)
- NCT02621021 · 170 participants · Phase 2
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
- NCT04094701 · 170 participants · NA
Hip Arthroscopy Postoperative Opioid Demands
- NCT04166409 · 170 participants · Phase 3
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI